Bionaturis, a biotechnology company listing at the Spanish MAB, participates in the public-private consortium ADELIS, led by Laboratorios Rovi and involving, besides Bionaturis, the companies Biomedal, Vaxdyn, Althia, and research groups from Virgen del Rocio Hospital, University of Granada, University of Sevilla, University of Cadiz and, Genyo as well. The project, which aims to an overall optimization of drug delivery systems, will last two years and will involve an estimated 2.6 million € global investment. The initiative is funded by the FEDER-INNTERCONECTA program, coordinated by The Centre for Industrial Technological Development (CDTI, in Spanish).
The activities and goals of Bionaturis within the project are framed in the seek for alternative solutions to the use of traditional antibiotics and tackling the alarming growth of antibacterial resistance. The emergence of multi-resistant bacterial strains is a growing problem of great concern for international health authorities. According to World Health Organization (WHO), a phenomena of resistance appears in 20% of patients treated for tuberculosis and are causing the majority of nosocomial infections acquired in hospitals, leading to more than 300,000 deaths annually in Europe and USA.
From animals to people
The problem is also transferred to animal health. New York Times has recently published a study showing that a majority of 30 antibiotics used in animal feed are linked to the increase of the phenomena of resistance in humans. Bionaturis addresses the problem by a pioneering approach proposing a collection of antimicrobial peptides (AMPs), some of them produced by the FLYLIFE system. Along the project, those AMPs will be tested in animal models using cutting-edge drug delivery systems originated from ADELIS. As a final outcome Bionaturis expects to obtain efficacy and safety data of the tested AMPs in mice models.
Juan José […]